Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02926690
Title Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors OncoTherapy Science, Inc.
Indications

triple-receptor negative breast cancer

breast cancer

Therapies

OTS167

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.